Literature DB >> 10579343

Parathyroid hormone activates mitogen-activated protein kinase in opossum kidney cells.

J A Cole1.   

Abstract

Many G protein-coupled receptor agonists activate p42/p44 mitogen-activated protein kinase (MAPK), using signaling pathways that are a function of receptor, G protein-coupled, and effector complement. In opossum kidney (OK) cells, activation of endogenous PTH receptors caused a time- (peak within 15-30 min, sustained for approximately 2 h) and dose-dependent (EC50 approximately 3 x 10(-10) M) activation of MAPK. Immunoblot analysis with an activation- specific MAPK antibody indicated that PTH activated both p42 and p44 MAPK. Epidermal growth factor (EGF) also activated p42 and p44MAPK in a time- (peak at 5 min, return to basal within 2 h) and dose-dependent (EC50 approximately 3 ng/ml) fashion. PTH-dependent MAPK activation was mimicked by the protein kinase C activator (PKC) phorbol myristate acetate (PMA), and the protein kinase A activators 8 bromo-cAMP (8-Br-cAMP) and forskolin but was not affected by pertussis toxin pretreatment. PMA or 8-Br-cAMP pretreatment blocked MAPK activation by reexposure to each kinase activator but caused no significant reduction in MAPK activation by PTH. MAPK activation by PTH, EGF, and 8-Br-cAMP was inhibited by the MAPK kinase inhibitor PD98059 and an EGF receptor (EGFR)-selective inhibitor tyrphostin AG1478. AG1478 also blocked MAPK activation by insulin-like growth factor-1 and platelet-derived growth factor. EGF and PTH caused time- and AG1478-sensitive phosphorylation of the EGFR, but EGFR desensitization did not affect MAPK activation by PTH. EGF, PMA, and low doses of PTH (10(12) to 10(-9) M) stimulated while 8-Br-cAMP and high doses of PTH (10(-8) to 10(-6) M) inhibited [3H]thymidine uptake. These data demonstrate that PTH activates MAPK and suggest that PKC, protein kinase A, and the EGFR play roles in PTH signaling. The biphasic effect of PTH on DNA synthesis suggests that MAPK activation by the hormone leads to distinct cellular responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579343     DOI: 10.1210/endo.140.12.7173

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  15 in total

1.  Effects of age on parathyroid hormone signaling in human marrow stromal cells.

Authors:  Shuanhu Zhou; Ericka M Bueno; Sung Won Kim; Ilaria Amato; Longxiang Shen; Jochen Hahne; Ilan Bleiberg; Paul Morley; Julie Glowacki
Journal:  Aging Cell       Date:  2011-05-25       Impact factor: 9.304

2.  Disruption of parathyroid hormone and parathyroid hormone-related peptide receptor phosphorylation prolongs ERK1/2 MAPK activation and enhances c-fos expression.

Authors:  Hesham A Tawfeek; Abdul B Abou-Samra
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-03-13       Impact factor: 4.310

Review 3.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

4.  A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation.

Authors:  Diane Gesty-Palmer; Pat Flannery; Ling Yuan; Leonor Corsino; Robert Spurney; Robert J Lefkowitz; Louis M Luttrell
Journal:  Sci Transl Med       Date:  2009-10-07       Impact factor: 17.956

Review 5.  EGFR signaling in breast cancer: bad to the bone.

Authors:  John Foley; Nicole K Nickerson; Seungyoon Nam; Kah Tan Allen; Jennifer L Gilmore; Kenneth P Nephew; David J Riese
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

Review 6.  Heterotrimeric G proteins in the control of parathyroid hormone actions.

Authors:  Murat Bastepe; Serap Turan; Qing He
Journal:  J Mol Endocrinol       Date:  2017-05       Impact factor: 5.098

Review 7.  At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone.

Authors:  John Foley; Nicole Nickerson; David J Riese; Peter C Hollenhorst; Gwendolen Lorch; Anne M Foley
Journal:  Odontology       Date:  2012-06-10       Impact factor: 2.634

8.  High prevalence of simple kidney cysts in patients with primary hyperparathyroidism.

Authors:  S Corbetta; C Eller-Vainicher; L Vicentini; S Carnicelli; F Sardanelli; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2009-05-26       Impact factor: 4.256

9.  β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.

Authors:  Diane Gesty-Palmer; Ling Yuan; Bronwen Martin; William H Wood; Mi-Hye Lee; Michael G Janech; Lam C Tsoi; W Jim Zheng; Louis M Luttrell; Stuart Maudsley
Journal:  Mol Endocrinol       Date:  2013-01-11

10.  Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone.

Authors:  Shibing Yu; Renny T Franceschi; Min Luo; Jie Fan; Di Jiang; Huiling Cao; Tae-Geon Kwon; Yumei Lai; Jian Zhang; Kenneth Patrene; Kurt Hankenson; G David Roodman; Guozhi Xiao
Journal:  PLoS One       Date:  2009-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.